Thyrocare Technologies has announced a final dividend of Rs. 7.00 per share for the 2025-26 financial year. The Board also approved the re-appointment of its leadership, key changes to the Board of Directors, and an investment of up to Rs. 5.50 crores in its subsidiary, Think Health Diagnostics. Furthermore, the company is updating its Memorandum of Association to broaden its operational scope within the diagnostic and healthcare ecosystem.
Financial Performance and Dividend
The Board of Directors has recommended a final dividend of Rs. 7.00 per equity share for the financial year ended March 31, 2026. This follows an interim dividend of Rs. 7.00 per share (pre-bonus adjustment) already distributed, bringing the total dividend for the fiscal year to Rs. 9.33 per equity share (post-bonus adjustment). The final payout remains subject to approval by shareholders at the upcoming Annual General Meeting.
Strategic Leadership and Board Changes
Mr. Rahul Franklin Guha has been re-appointed as the Chairman, Managing Director, and CEO for a five-year term, effective May 4, 2027, through May 3, 2032. Additionally, the company is strengthening its Board with the appointment of Mr. Uday Patel Kadam and Mr. Gaurav Verma as Additional Directors, effective May 8, 2026. These appointments follow the resignations of Mr. Dharmil Nirupam Sheth and Dr. Dhaval Rajesh Shah, both of whom stepped down from their respective roles effective May 7, 2026.
Investment and Operational Growth
Thyrocare has approved a capital infusion of up to Rs. 5.50 crores into its wholly-owned subsidiary, Think Health Diagnostics Private Limited. This investment is designed to support the subsidiary’s business operations and meet its capital expenditure requirements. Furthermore, the company is updating its Memorandum of Association to align with the Companies Act, 2013, and to expand its business scope to include a wider range of healthcare services, digital platforms, and diagnostic products.
Governance and Auditor Updates
As part of its governance renewal, the Board has recommended the appointment of Price Waterhouse Chartered Accountants LLP as the new Statutory Auditors for a five-year term, succeeding M S K A & Associates LLP upon the conclusion of the 26th Annual General Meeting. Additionally, Jitender Navneet & Co. has been appointed as the Cost Auditor for the 2026-27 financial year.
Source: BSE
